Asia Pacific Alzheimer Diagnosis and Treatment Market Trends

Growth Drivers

• Growing Prevalence of Alzheimer’s Disease – Between now and 2050, the number of dementia sufferers in the Asia-Pacific area will triple. More than half of all dementia sufferers globally will reside in the Asia Pacific region by the middle of the century.

• Government Initiatives for Alzheimer’s Patients – World Health Organization unveiled an 8-year plan, the “Global Action Plan” for people suffering from dementia. This plan aims to guide member states in creating new strategies and evaluating the pre-existed plans. As of December 2018, 16 plans are available in the Region of Europe (EURO), 5 are in the Region of the Americas (AMRO), 4 are in the Region of the Western Pacific (WPRO), 1 is in the Region of the Eastern Mediterranean (EMRO), and 1 is in the Region of Southeast Asia (SEARO)

• Increasing Development of Drugs for Alzheimer’s Disease – For instance, TauRx announced the result from the phase 3 trial of HMTM treatment curated for patients at the early stage of Alzheimer’s. The result indicated that the treatment aided the cognitive improvement and brain atrophy rate achieved similarity with a healthy person.

• Growing Geriatric Population – Alzheimer’s disease is the most common reason for the dependency in the elderly population. According to the United Nations, the Asia-Pacific population is aging the fastest of all the regions in the world. Around 60% of the population in the region which is 630 million people are 60 years old or above. However, it is expected that the geriatric population in the region is likely to reach 1.3 billion by 2050.

• Rising Investment for the R&D Healthcare Sector – Influx of investment in the healthcare sector is expected to advance the development of Alzheimer’s treatment, diagnostics methods, and dementia care products. According to the Asia-Pacific Trade and Investment Trends 2022/2023, the pharmaceutical industry attracted a higher amount of FDI worth USD 32 billion between 2008-2021, followed by medical devices and healthcare garnering an investment of USD 20 billion and USD 10.8 billion, respectively.

Challenges

• Lack of education and awareness of Alzheimer’s disease- Alzheimer’s and dementia is the 7^th largest cause of death and significant contributor to dependency among the elderly. However, public awareness about the disease is significantly low which results in low or no diagnosis of the disease and worsens the condition of the person. Therefore, a lack of education associated with the disease is expected to hamper the market growth.
• The procedure of drug development is costly and time-consuming
• Higher rate of failure of drug clinical trial